Click to copy
Click to copy

Ridgefield pharma resolves legal impasse for Humira rival

Alexander SouleMay 14, 2019

Boehringer Ingelheim Pharmaceuticals announced a resolution of its litigation with AbbVie that had delayed its introduction of a “biosimilar” alternative to the AbbVie blockbuster drug Humira.

Under the agreement, Boehringer Ingelheim will be able to begin selling its Cyltezo alternative to Humira beginning in July 2023.

Boehringer Ingelheim is based in Germany with its U.S. pharmaceutical headquarters in Ridgefield. The settlement is limited to U.S. sales only, with the companies not providing financial terms of their licensing agreement.

Alex.Soule@scni.com; 203-842-2545; @casoulman

All contents © copyright 2019 The Associated Press. All rights reserved.